# Advancing Science. Enhancing Lives.

Navigating CDER: What You Should Know for Effective Engagement

Alliance FOR AGING RESEARCH

FDA Public Workshop FDA White Oak Campus May 12, 2017

Cynthia A. Bens, Vice President of Public Policy

## **About the Alliance**










### **WHO WE ARE**

The Alliance for Aging Research is the leading non-profit organization dedicated to accelerating the pace of scientific discoveries and their application in order to vastly improve the universal human experience of aging and health.

www.agingresearch.org



### **ACT-AD Coalition**



### **53 Non-profit Members**

### **Science Advisory Board**

Paul Aisen, M.D. Jeffrey L. Cummings, M.D., Sc.D. Phyllis E. Greenberger, MSW

Rusty Katz, M.D.

George Perry, Ph.D.

Reisa A. Sperling, M.D., MMSc.

### **Industry Partners**

Anavex

Avanir

Axovant

Biogen

Eisai

Eli Lilly and Company

Genentech

Janssen

Lundbeck


Merck

Otsuka

Advancing Science. Enhancing Lives.



### **AIM Coalition**



### **Industry Partners**

Abbott
Astellas
Cytokinetics
Hologic
Nutricia Advanced Medical Nutrition

### 35 Non-profit Members

**Science Advisory Board** Jack M. Guralnik, M.D., Ph.D., MPH William J. Evans, Ph.D. Luigi Ferrucci, M.D., Ph.D. Roger A. Fielding, Ph.D. Linda P. Fried, M.D., MPH Bret Goodpaster, Ph.D. Tamara B. Harris, M.D., M. Stephen Kritchevsky, Ph.D. Jay Magaziner, Ph.D., M.S. Hyg. Marco Pahor, M.D. Ronenn Roubenoff, M.D., MHS Stephanie Studenski, M.D., MPH Bruno Vellas, M.D., Sc.D.



# **Key Lessons**

- Educate yourself on the clinical trial process
- Learn what information is useful for regulatory purposes
- Reconcile your goals with those of the research community and regulated industry
- Work with other advocacy groups in your space
- Listen when FDA speaks about your disease
- Successful engagement does not always=drug approvals
- Acknowledge when FDA has gone above and beyond





#### Office of the Center Director

Janet Woodcock, M.D. Theresa Mullin, Ph.D. Sara Eggers, Ph.D.

### Office of Drug Evaluation-1

Ellis Unger, M.D. Bob Temple, M.D.

### **Division of Neurology Products**

Billy Dunn, M.D. Eric Bastings, M.D. Nick Kozauer, M.D. Kun Jin, Ph.D., M.S.

### <u>Division of Metabolism and</u> <u>Endocrinology Products</u>

Jean-Marc Guettier, M.D. Marina Zemskova, M.D.

#### **Clinical Outcomes Assessment**

Elektra Papadopulous, M.D., M.P.H. Wen Hung Chen, Ph.D.

### <u>Professional Affairs and Stakeholder</u>

**Engagement** 

John Whyte, M.D. Rea Blakey

## Office of Health and Constituent Affairs

Salina Prasad, M.S., M.B.A

# Advancing Science. Enhancing Lives.

for Aging Research  $on. \$ 

Alliance

Thank you for your attention.
Questions? Comments?

Cynthia Bens, Vice President of Public Policy

Email: <a href="mailto:cbens@agingresearch.org">cbens@agingresearch.org</a>

Phone: 202-688-1230